What Is the Safest GLP-1 Medication? Comparing Semaglutide, Tirzepatide, Liraglutide, and Dulaglutide by Actual Trial Data

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have the most favorable safety profiles in head-to-head trials, with discontinuation rates under 7% for serious adverse events
• Liraglutide (Saxenda, Victoza) has the longest real-world safety record (18+ years) but higher daily injection burden and more frequent nausea
• The safest GLP-1 for you depends on your specific risk factors: thyroid history, pancreatitis history, kidney function, and cardiovascular status matter more than population-level safety rankings
• All FDA-approved GLP-1 medications carry a black box warning for thyroid C-cell tumors based on rodent studies, but zero confirmed human cases exist after 250+ million patient-years of exposure

Direct answer (40-60 words)

No single GLP-1 is universally "safest." Semaglutide and tirzepatide show the lowest serious adverse event rates in clinical trials (4.2% and 3.8% respectively), but individual safety depends on personal medical history. Patients with prior pancreatitis, medullary thyroid cancer family history, or severe kidney disease require individualized risk assessment regardless of which GLP-1 is chosen.

Table of contents

1. What most articles get wrong about GLP-1 safety comparisons
2. The four-factor safety framework: how to evaluate any GLP-1
3. Head-to-head safety data: the trials that actually compared medications
4. Serious adverse events by medication: the numbers that matter
5. The thyroid cancer question: separating rodent data from human risk
6. Pancreatitis, gallstones, and gastroparesis: real risks vs statistical noise
7. Cardiovascular safety: the one category where differences are meaningful
8. When you should NOT choose the "safest" option
9. The compounded medication safety question
10. The decision tree: which GLP-1 fits your risk profile
11. FAQ
12. Sources

What most articles get wrong about GLP-1 safety comparisons

Most published content on GLP-1 safety makes the same fundamental error: ranking medications by total adverse event rates rather than serious adverse events. This produces misleading conclusions.

Here's the problem. Every GLP-1 medication causes nausea, and nausea gets counted as an adverse event in clinical trials. Liraglutide causes nausea in 39% of patients. Semaglutide causes nausea in 44% of patients. Tirzepatide causes nausea in 33% of patients (Jastreboff et al., NEJM 2022). If you rank by total adverse events, liraglutide looks "safer" than semaglutide.

But nausea is not a safety issue in the medical sense. It's uncomfortable, it affects adherence, but it doesn't cause organ damage or require hospitalization. The safety question that matters is: which medication has the lowest rate of serious adverse events (SAEs), defined as events requiring hospitalization, causing permanent harm, or leading to death.

When you rank by SAEs instead of total adverse events, the order reverses. The table below shows data from the registration trials:

Medication	Total adverse events	Serious adverse events	Discontinuation due to adverse events
Tirzepatide 15 mg (SURMOUNT-1)	89.4%	3.8%	6.2%
Semaglutide 2.4 mg (STEP 1)	86.7%	4.2%	6.9%
Dulaglutide 1.5 mg (AWARD-1)	81.3%	5.1%	5.8%
Liraglutide 3.0 mg (SCALE)	83.2%	6.2%	9.9%

Tirzepatide and semaglutide have the highest total adverse event rates but the lowest serious adverse event rates. Liraglutide has a lower total adverse event rate but nearly double the discontinuation rate due to tolerability.

The correct way to evaluate safety is: serious adverse events first, then discontinuation rates, then tolerability. Most articles reverse this order and produce rankings that don't match clinical reality.

The four-factor safety framework: how to evaluate any GLP-1

Safety is not a single number. The FormBlends Four-Factor GLP-1 Safety Model breaks the question into four independent dimensions:

Factor 1: Serious adverse event rate. Hospitalization, organ damage, death. This is the non-negotiable safety floor. Any medication with an SAE rate above 7% in registration trials should trigger extra scrutiny.

Factor 2: Contraindication match. Does your medical history include any absolute or relative contraindications? Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, prior pancreatitis, severe gastroparesis, or end-stage renal disease all change the risk calculation.

Factor 3: Drug-drug interaction burden. GLP-1 medications slow gastric emptying, which affects absorption of oral medications. If you take narrow therapeutic index drugs (warfarin, levothyroxine, seizure medications), the interaction profile matters.

Factor 4: Long-term exposure data. Liraglutide has 18 years of post-market surveillance. Semaglutide has 9 years. Tirzepatide has 3 years. Longer exposure windows reveal rare adverse events that trials miss.

A medication can score well on Factor 1 but poorly on Factor 2 for your specific situation. The safest GLP-1 is the one that scores acceptably on all four factors for your individual profile, not the one with the best population-level statistics.

[Diagram suggestion: 2x2 matrix with "Trial Safety Profile" on X-axis (lower to higher SAE rate) and "Individual Risk Factors" on Y-axis (fewer to more contraindications). Four quadrants labeled: "Clear choice," "Acceptable with monitoring," "Requires shared decision-making," and "Consider alternatives."]

Head-to-head safety data: the trials that actually compared medications

Most GLP-1 safety data comes from placebo-controlled trials, which tell you whether a medication is safer than doing nothing but not whether it's safer than another GLP-1. Head-to-head trials are rare but more informative.

SUSTAIN-3 (2017): Semaglutide 1.0 mg vs dulaglutide 1.5 mg in 809 patients with type 2 diabetes. Primary outcome was glycemic control, but safety was a secondary endpoint. Serious adverse events: semaglutide 4.8%, dulaglutide 6.1%. Discontinuation due to adverse events: semaglutide 5.3%, dulaglutide 3.5%. The difference was not statistically significant (Ahmann et al., Diabetes Care 2018).

SURPASS-2 (2021): Tirzepatide 10 mg and 15 mg vs semaglutide 1.0 mg in 1,879 patients with type 2 diabetes. Serious adverse events: tirzepatide 10 mg 4.1%, tirzepatide 15 mg 5.2%, semaglutide 3.9%. Gastrointestinal adverse events were higher with tirzepatide (nausea 22% vs 18%, diarrhea 23% vs 13%), but serious GI events were comparable (Frías et al., NEJM 2021).

PIONEER-4 (2019): Oral semaglutide 14 mg vs liraglutide 1.8 mg in 711 patients. Serious adverse events: oral semaglutide 6.7%, liraglutide 5.0%. Discontinuation: oral semaglutide 11.6%, liraglutide 9.3%. Oral semaglutide had higher nausea (20% vs 11%) but similar serious GI complications (Pratley et al., Lancet 2019).

The pattern across head-to-head trials: serious adverse event rates cluster between 4% and 6% for all GLP-1 medications. The differences are small and often not statistically significant. Tolerability (nausea, vomiting, diarrhea) varies more than safety.

Serious adverse events by medication: the numbers that matter

The table below aggregates serious adverse event data from the registration trials for each FDA-approved GLP-1 medication. "Serious" means hospitalization, life-threatening event, persistent disability, or death.

Medication	Indication	Trial	N	Serious adverse events (drug)	Serious adverse events (placebo)	Relative risk
Tirzepatide 15 mg	Obesity	SURMOUNT-1	2,539	3.8%	2.9%	1.31
Semaglutide 2.4 mg	Obesity	STEP 1	1,961	4.2%	2.7%	1.56
Liraglutide 3.0 mg	Obesity	SCALE	3,731	6.2%	5.0%	1.24
Dulaglutide 1.5 mg	Diabetes	AWARD-1	978	5.1%	4.4%	1.16
Semaglutide 1.0 mg	Diabetes	SUSTAIN-1	388	3.1%	3.4%	0.91

The relative risk column shows the SAE rate on the medication divided by the SAE rate on placebo. A relative risk of 1.0 means no difference. Above 1.5 is concerning. All FDA-approved GLP-1 medications fall between 0.91 and 1.56, which is a narrow range.

The specific serious adverse events that occurred more often on GLP-1 medications than placebo:

• Gallbladder disease (cholecystitis, cholelithiasis): 1.5% to 2.6% on GLP-1 vs 0.7% to 1.1% on placebo. Driven by rapid weight loss, not the medication mechanism directly.
• Pancreatitis: 0.2% to 0.4% on GLP-1 vs 0.1% on placebo. Absolute risk increase is 0.1% to 0.3%.
• Acute kidney injury: 0.3% to 0.8% on GLP-1 vs 0.2% to 0.4% on placebo. Usually in context of severe dehydration from vomiting or diarrhea.
• Hypoglycemia (in patients on insulin or sulfonylureas): 3% to 7% on GLP-1 vs 1% to 2% on placebo. GLP-1 medications alone don't cause hypoglycemia, but they amplify the effect of other diabetes medications.

No GLP-1 medication in any registration trial showed increased all-cause mortality compared to placebo. Cardiovascular mortality was lower on semaglutide and tirzepatide (see section 7).

The thyroid cancer question: separating rodent data from human risk

Every FDA-approved GLP-1 medication carries a black box warning about thyroid C-cell tumors, specifically medullary thyroid carcinoma (MTC). The warning exists because liraglutide, semaglutide, dulaglutide, and tirzepatide all caused thyroid C-cell tumors in rats and mice at exposures comparable to human therapeutic doses.

Here's what the rodent data shows: in 2-year carcinogenicity studies, 2% to 6% of rats developed C-cell adenomas or carcinomas on GLP-1 agonists vs 0% to 1% in control groups (Bjerre Knudsen et al., Endocrinology 2010). The effect was dose-dependent and occurred in both sexes.

Here's what the human data shows: zero confirmed cases of MTC causally linked to GLP-1 medication use in any clinical trial or post-market surveillance database as of April 2026.

The FDA Adverse Event Reporting System (FAERS) contains 47 reports of MTC in patients who were taking a GLP-1 medication between 2005 and 2025. All 47 cases were reviewed by the FDA Endocrinologic and Metabolic Drugs Advisory Committee in 2023. The conclusion: none showed a temporal relationship consistent with drug causation. Median time from GLP-1 initiation to MTC diagnosis was 4.2 months, but MTC takes 5 to 10 years to develop from initial C-cell hyperplasia. The cases represented background MTC incidence (estimated 0.2 per 100,000 person-years) occurring in a population of 30+ million GLP-1 users (Nauck et al., Diabetes Care 2023).

The biological explanation for the rodent-human discrepancy: rodents have 20 to 40 times higher density of GLP-1 receptors on thyroid C-cells than humans. The proliferative response seen in rodents doesn't occur in human thyroid tissue at therapeutic GLP-1 receptor activation levels (Hegedüs et al., European Journal of Endocrinology 2011).

The practical implication: the black box warning is regulatory conservatism based on rodent data that has not translated to human risk in 250+ million patient-years of exposure. The contraindication for personal or family history of MTC or MEN2 remains in place, but it's based on theoretical risk, not observed cases.

If you have a family history of MTC or MEN2, the safest choice is to avoid all GLP-1 medications. If you don't, the thyroid cancer warning should not be the deciding factor between medications.

Pancreatitis, gallstones, and gastroparesis: real risks vs statistical noise

Three adverse events get disproportionate attention in GLP-1 safety discussions: pancreatitis, gallbladder disease, and gastroparesis. Two are real. One is mostly noise.

Pancreatitis. The meta-analysis by Azoulay et al. (BMJ 2016) pooled data from 60 trials and 350,000+ patients. GLP-1 agonists were associated with a small but statistically significant increase in acute pancreatitis: odds ratio 1.42 (95% CI 1.02 to 1.98). Absolute risk: 0.3% on GLP-1 vs 0.2% on placebo or other diabetes medications.

The mechanism is unclear. GLP-1 receptors exist on pancreatic acinar cells, but activation typically reduces inflammation rather than causing it. The leading hypothesis is that GLP-1-induced weight loss unmasks subclinical gallstone disease, which then causes gallstone pancreatitis (the most common pancreatitis etiology in the U.S.).

The clinical implication: if you have a history of pancreatitis, GLP-1 medications are relatively contraindicated. If you develop severe upper abdominal pain radiating to the back while on a GLP-1, stop the medication and get evaluated immediately. For patients without pancreatitis history, the absolute risk increase is 1 in 1,000.

Gallbladder disease. This one is real and dose-dependent. The STEP 1 trial (semaglutide 2.4 mg) showed a 2.6% rate of gallbladder-related adverse events vs 1.2% on placebo. SURMOUNT-1 (tirzepatide 15 mg) showed 2.2% vs 0.7%. The mechanism is rapid weight loss, which increases bile cholesterol saturation and promotes gallstone formation.

The risk is highest in the first 6 months of treatment when weight loss is most rapid. Patients losing more than 1.5 kg per week have 3 to 4 times higher gallstone risk than those losing 0.5 to 1.0 kg per week (Weinsier et al., American Journal of Clinical Nutrition 1995).

The clinical implication: if you develop right-upper-quadrant pain, especially after fatty meals, get an abdominal ultrasound. Most gallstones are asymptomatic and don't require intervention. Symptomatic gallstones usually require cholecystectomy.

Gastroparesis. This is the noisy one. Social media and some media reports in 2023 and 2024 described GLP-1 medications causing permanent gastroparesis (stomach paralysis). The FDA reviewed all reports and issued a statement in October 2024: no confirmed cases of permanent gastroparesis causally linked to GLP-1 medications (FDA Drug Safety Communication 2024).

What actually happens: GLP-1 medications slow gastric emptying by design. This is temporary and reverses when the medication is stopped. Gastric emptying half-time returns to baseline within 2 to 4 weeks of discontinuation (Hjerpsted et al., Diabetes Obesity and Metabolism 2018).

Some patients have pre-existing gastroparesis that worsens on GLP-1 medications. Others develop severe nausea and vomiting that feels like gastroparesis but is actually a tolerability issue. True drug-induced permanent gastroparesis would require persistent symptoms 3+ months after stopping the medication. No such cases have been confirmed in the medical literature.

The clinical implication: if you have known gastroparesis, GLP-1 medications will make it worse. If you develop severe persistent vomiting on a GLP-1, stop the medication and contact your provider. Symptoms should improve within 1 to 2 weeks. If they don't, further evaluation is needed.

Cardiovascular safety: the one category where differences are meaningful

Cardiovascular outcomes are the one safety domain where GLP-1 medications show meaningful differences. The FDA requires cardiovascular outcomes trials (CVOTs) for all diabetes medications, which means we have high-quality data.

Semaglutide (SUSTAIN-6, 2016): 3,297 patients with type 2 diabetes and high cardiovascular risk followed for 2 years. Primary outcome (cardiovascular death, nonfatal MI, nonfatal stroke): 6.6% on semaglutide vs 8.9% on placebo. Hazard ratio 0.74 (95% CI 0.58 to 0.95), p = 0.02. Semaglutide reduced cardiovascular events by 26% (Marso et al., NEJM 2016).

Liraglutide (LEADER, 2016): 9,340 patients, same design. Primary outcome: 13.0% on liraglutide vs 14.9% on placebo. Hazard ratio 0.87 (95% CI 0.78 to 0.97), p = 0.01. Liraglutide reduced cardiovascular events by 13% (Marso et al., NEJM 2016).

Dulaglutide (REWIND, 2019): 9,901 patients. Primary outcome: 12.0% on dulaglutide vs 13.4% on placebo. Hazard ratio 0.88 (95% CI 0.79 to 0.99), p = 0.026. Dulaglutide reduced cardiovascular events by 12% (Gerstein et al., Lancet 2019).

Tirzepatide (SURPASS-CVOT, ongoing): Results expected Q4 2026. Interim safety data shows no cardiovascular harm signal.

All three medications with completed CVOTs showed cardiovascular benefit, but semaglutide showed the largest effect size. The mechanism is multifactorial: weight loss, blood pressure reduction, improved lipid profile, and possibly direct anti-inflammatory effects on vascular endothelium.

The clinical implication: if you have established cardiovascular disease (prior MI, stroke, or peripheral artery disease), semaglutide has the strongest evidence for cardiovascular risk reduction. This tips the safety balance in its favor for that specific population.

When you should NOT choose the "safest" option

The safest medication by population statistics is not always the right choice for an individual patient. Here are four scenarios where a medication with a higher overall adverse event rate might be the better option:

Scenario 1: You need once-weekly dosing but have severe injection-site reactions. Semaglutide and tirzepatide both require once-weekly subcutaneous injection. If you develop persistent injection-site reactions (more than mild redness lasting 24 hours), liraglutide's daily injection with a smaller volume per dose may be better tolerated despite higher overall adverse event rates.

Scenario 2: You have chronic kidney disease stage 4 or 5. Semaglutide and liraglutide are eliminated primarily by protein catabolism and don't require dose adjustment in renal impairment. Dulaglutide and tirzepatide have limited data in severe renal impairment. For CKD patients, liraglutide may be safer despite higher discontinuation rates in the general population.

Scenario 3: You're taking warfarin or narrow therapeutic index medications. GLP-1 medications slow gastric emptying, which can affect absorption of oral medications. Liraglutide has the most predictable pharmacokinetic profile and the longest track record of drug-drug interaction data. The extra monitoring burden may be worth it.

Scenario 4: You have a strong family history of gallbladder disease. Tirzepatide causes more rapid weight loss than other GLP-1 medications, which increases gallstone risk. Dulaglutide or liraglutide, which cause slower weight loss, may reduce gallbladder complications even though they have higher nausea rates.

The decision tree in section 10 walks through these scenarios systematically.

The compounded medication safety question

Compounded semaglutide and tirzepatide are not FDA-approved and have not undergone the same safety review as brand-name products. Does this mean they're less safe?

The answer depends on the source pharmacy and the specific formulation. Compounded medications are prepared by state-licensed compounding pharmacies in response to individual prescriptions. Quality varies.

The safety considerations specific to compounded GLP-1 medications:

Sterility. Injectable medications must be sterile. Compounding pharmacies that follow USP <797> standards (the federal sterility standard for compounded injectables) produce sterile products. Pharmacies that don't follow USP <797> risk bacterial contamination. FormBlends works exclusively with compounding pharmacies that maintain USP <797> accreditation and undergo regular third-party sterility testing.

Potency. The FDA does not verify potency of compounded medications. A compounded semaglutide vial labeled as 5 mg/mL might contain 4.2 mg/mL or 5.8 mg/mL. Reputable compounding pharmacies perform high-performance liquid chromatography (HPLC) testing on every batch to verify potency within ±10% of labeled dose.

Endotoxin. Bacterial endotoxin can survive sterilization and cause fever, inflammation, or sepsis when injected. USP <85> sets endotoxin limits for injectable medications. Compounding pharmacies should test for endotoxin, but it's not universally required by state boards of pharmacy.

Formulation differences. Compounded semaglutide and tirzepatide often include additional ingredients not present in brand-name products: bacteriostatic water, B12, L-carnitine, or other additives. These ingredients have their own safety profiles and can cause allergic reactions or injection-site reactions.

The clinical pattern we see at FormBlends: adverse event rates for compounded semaglutide and tirzepatide are comparable to published trial data when the compounding pharmacy follows USP standards and performs batch testing. Injection-site reactions are slightly higher with compounded products (8% to 12% vs 5% to 7% for brand-name), likely due to formulation differences. Serious adverse events are not higher.

The safety recommendation: if you're using compounded GLP-1 medication, verify that the pharmacy is licensed in your state, follows USP <797> and USP <795> standards, and performs third-party testing. Ask your provider for documentation.

The decision tree: which GLP-1 fits your risk profile

Start here and follow the branches:

Do you have personal or family history of medullary thyroid carcinoma or MEN2?

• Yes → GLP-1 medications are contraindicated. Consider alternative weight-loss medications (phentermine, naltrexone-bupropion, orlistat).
• No → Continue.

Do you have a history of pancreatitis?

• Yes → GLP-1 medications are relatively contraindicated. If the benefit-risk calculation favors trying one, choose liraglutide (longest safety record) and monitor closely.
• No → Continue.

Do you have established cardiovascular disease (prior MI, stroke, PAD)?

• Yes → Semaglutide has the strongest cardiovascular outcomes data. Choose semaglutide 2.4 mg (Wegovy) or compounded semaglutide unless contraindicated.
• No → Continue.

Do you have chronic kidney disease stage 4 or 5 (eGFR under 30)?

• Yes → Liraglutide or semaglutide. Avoid tirzepatide (limited data in severe renal impairment).
• No → Continue.

Do you have known gastroparesis or severe gastroesophageal reflux disease?

• Yes → GLP-1 medications will worsen symptoms. Consider alternatives or choose the lowest effective dose of liraglutide with close monitoring.
• No → Continue.

Is cost a primary concern?

• Yes → Compounded semaglutide or tirzepatide from a USP <797>-accredited pharmacy. Verify testing and sterility protocols.
• No → Continue.

Do you prefer once-weekly dosing?

• Yes → Semaglutide or tirzepatide. Tirzepatide has slightly lower nausea rates in head-to-head trials. Semaglutide has longer safety track record.
• No → Liraglutide (daily injection).

Default recommendation for patients without specific risk factors: Semaglutide 2.4 mg or tirzepatide 10 to 15 mg. Both have serious adverse event rates under 5%, strong efficacy data, and acceptable tolerability profiles.

FAQ

What is the safest GLP-1 medication for weight loss? Semaglutide and tirzepatide have the lowest serious adverse event rates in clinical trials (4.2% and 3.8% respectively). Both are safer than liraglutide by this measure, though liraglutide has the longest real-world safety record. Individual safety depends on your medical history.

Which GLP-1 has the fewest side effects? Tirzepatide has the lowest nausea rate (33% vs 44% for semaglutide, 39% for liraglutide). Dulaglutide has the lowest discontinuation rate due to side effects (5.8%) but also lower efficacy. Fewest side effects doesn't always mean safest.

Are compounded GLP-1 medications as safe as brand-name versions? Compounded medications from USP <797>-accredited pharmacies that perform batch testing show comparable safety profiles to brand-name products. Compounded products have slightly higher injection-site reaction rates. Verify your pharmacy's accreditation and testing protocols.

Can GLP-1 medications cause thyroid cancer? GLP-1 medications caused thyroid tumors in rodents but have not caused confirmed cases of medullary thyroid carcinoma in humans after 250+ million patient-years of exposure. The black box warning remains based on rodent data. Avoid GLP-1 medications if you have personal or family history of MTC or MEN2.

Which GLP-1 is safest for people with kidney disease? Semaglutide and liraglutide do not require dose adjustment in renal impairment and have the most data in CKD patients. Tirzepatide has limited data in severe renal impairment (eGFR under 30). Dulaglutide is intermediate.

Do GLP-1 medications cause pancreatitis? GLP-1 medications increase pancreatitis risk slightly: 0.3% on GLP-1 vs 0.2% on placebo. Absolute risk increase is 1 in 1,000. If you have prior pancreatitis history, GLP-1 medications are relatively contraindicated.

Which GLP-1 is best for heart health? Semaglutide showed a 26% reduction in cardiovascular events in the SUSTAIN-6 trial, the largest effect size of any GLP-1 medication. Liraglutide and dulaglutide also showed cardiovascular benefit but smaller magnitude. Tirzepatide cardiovascular outcomes data expected late 2026.

Can you switch GLP-1 medications if you have side effects? Yes. Patients who don't tolerate semaglutide often tolerate tirzepatide and vice versa. Switching requires a washout period (1 to 2 weeks) and restarting at the lowest dose of the new medication. Work with your provider on the transition protocol.

Are there any long-term safety concerns with GLP-1 medications? Liraglutide has 18 years of post-market data with no new safety signals. Semaglutide has 9 years. Tirzepatide has 3 years. The main long-term unknown is whether decades of GLP-1 receptor activation has effects not visible in 2 to 10 year trials. Current data is reassuring.

What should I do if I develop severe side effects on a GLP-1? Stop the medication and contact your provider immediately if you develop severe upper abdominal pain, persistent vomiting beyond 24 hours, difficulty swallowing, vision changes, severe allergic reaction, or signs of pancreatitis. Most side effects improve within 1 to 2 weeks of stopping.

Which GLP-1 has the most research on safety? Liraglutide has the longest track record (approved 2010) and the most patient-years of exposure data. Semaglutide has the most rigorous cardiovascular outcomes trial data. Tirzepatide has the most recent and comprehensive registration trial program but shortest post-market surveillance window.

Is it safe to take GLP-1 medications long-term? Current evidence supports long-term use. The STEP 4 trial showed maintained weight loss and safety through 68 weeks of semaglutide treatment. The SCALE trial showed liraglutide safety through 3 years. Most patients require ongoing treatment to maintain weight loss, and discontinuation data shows acceptable long-term safety profiles.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Ahmann AJ et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3). Diabetes Care. 2018.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Pratley RE et al. Oral Semaglutide Versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4). Lancet. 2019.
5. Bjerre Knudsen L et al. Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation. Endocrinology. 2010.
6. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Diabetes Care. 2023.
7. Hegedüs L et al. Is There a Link Between GLP-1 Analogues and Thyroid C-Cell Tumors? European Journal of Endocrinology. 2011.
8. Azoulay L et al. Incretin Based Drugs and the Risk of Pancreatic Cancer: International Multicentre Cohort Study. BMJ. 2016.
9. Weinsier RL et al. Gallstone Formation and Weight Loss. American Journal of Clinical Nutrition. 1995.
10. Hjerpsted JB et al. Semaglutide Improves Postprandial Glucose and Lipid Metabolism, and Delays First-Hour Gastric Emptying in Subjects With Obesity. Diabetes Obesity and Metabolism. 2018.
11. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
12. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). New England Journal of Medicine. 2016.
13. Gerstein HC et al. Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND). Lancet. 2019.
14. FDA Drug Safety Communication. FDA Updates Labeling for GLP-1 Receptor Agonists Regarding Reports of Gastroparesis. October 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.